Winthrop Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Winthrop Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2K	Buy	6 +2	+50%	+$603	﹤0.01%	274
2026 Q1	$1K	Hold	4	–	–	﹤0.01%	304
2025 Q4	$2K	Buy	+4	New	+$1.77K	﹤0.01%	277
2025 Q1	–	Sell	-5	Closed	-$1K	–	329
2024 Q4	$1K	Hold	5	–	–	﹤0.01%	276
2024 Q3	$1K	Sell	5 -1	-17%	-$260	﹤0.01%	139
2024 Q2	$1K	Hold	6	–	–	﹤0.01%	134
2024 Q1	$1K	Hold	6	–	–	﹤0.01%	139
2023 Q4	$1.15K	Buy	+6	New	+$1.02K	﹤0.01%	248

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Winthrop Capital Management's ALNY Position: Q2 2026 in Review

Winthrop Capital Management increased its Alnylam Pharmaceuticals (ALNY) stake by 50% in Q2 2026, buying an estimated $603 and bringing the position to 6 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #274.

Winthrop Capital Management first reported a position in ALNY in Q4 2023 and has held it in 8 quarters since. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Winthrop Capital Management held 6 shares of Alnylam Pharmaceuticals worth $2K as of Q2 2026.
Winthrop Capital Management bought 2 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $603.
Alnylam Pharmaceuticals made up ﹤0.01% of Winthrop Capital Management's portfolio in Q2 2026, its #274 holding.
Winthrop Capital Management first reported a position in Alnylam Pharmaceuticals in Q4 2023 and has held it in 8 quarters since.
790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Winthrop Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.